Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN).
Gross N, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Wargo J, Weber R, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal Of Clinical Oncology 2022, 40: 9519-9519. DOI: 10.1200/jco.2022.40.16_suppl.9519.Peer-Reviewed Original ResearchPathologic complete responseOverall response rateCutaneous squamous cell carcinomaPhase II trialPathologic responseLong-term outcomesNeoadjuvant immunotherapySquamous cell carcinomaAdverse eventsCSCC-HNII trialCell carcinomaGrade 2 adverse eventsPilot phase II trialGrade 3 diarrheaMajor pathologic responsePathologic partial responseAdjuvant radiation therapyWarrants further investigationMedian followRECIST v1.1Adjuvant radiationPrimary endpointRecurrent diseaseSecondary endpoints